Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan

View source ↗

Summary

A completed real-world study evaluating change in disease activity and adverse events for Rinvoq (tofacitinib) in adults with ankylosing spondylitis in Japan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Ankylosing Spondylitis | Status: COMPLETED